News

Blood and plasma screening system gets CE mark


 

Blood in bags and vials
Photo by Daniel Gay

Abbott’s Alinity s System for blood and plasma screening has received the CE mark and is now available for use in countries that recognize the mark.

The Alinity s System is designed to screen blood and plasma faster and more efficiently than Abbott’s current systems.

The company said the additional automation and flexibility of the Alinity s System helps blood and plasma centers improve productivity and maintain accuracy without expanding the instrument footprint.

According to Abbott, the Alinity s System offers a number of new features. It expands capacity to run up to 600 tests per hour, and it increases walk-away time to a minimum of 3 hours.

The system also gives laboratory professionals the ability to continuously load and

unload samples and supplies without pausing or stopping the system.

The Alinity s System improves centers’ ability to track all activities and actions associated with the testing and processing of each donation in accordance with relevant legislation and requirements.

And the system features an intuitive software interface, menu design, and sample loading layout (shared with other Alinity instruments), making it easy for lab technicians to learn and use.

“When Abbott developed the Alinity s System, we considered the challenges that blood and plasma centers face today as well as in the future, such as adequate space, easier training, and more time for lab professionals to work away from the instrument,” said Daman Kowalski, divisional vice president of new product development in diagnostics at Abbott.

“In addressing these challenges, the Alinity s System has the potential to transform how quickly and accurately these centers can screen blood and plasma, which means we can deliver life-saving blood components to the people who need it the most.”

Recommended Reading

Transfusing oldest blood may harm patients
MDedge Hematology and Oncology
Assay could make blood supply safer, groups say
MDedge Hematology and Oncology
Blood products unharmed by drone trips
MDedge Hematology and Oncology
Artificial RBCs show promise in preclinical study
MDedge Hematology and Oncology
Restrictive transfusion strategy should be standard after HSCT, doc says
MDedge Hematology and Oncology
Sex-discordant transfusions don’t increase death risk
MDedge Hematology and Oncology
Improving cryopreservation of RBCs
MDedge Hematology and Oncology
Treating RBCs with NO may make them safer
MDedge Hematology and Oncology
Tranexamic acid safely reduces need for transfusion, study suggests
MDedge Hematology and Oncology
FDA approves blood screening assay
MDedge Hematology and Oncology